Explore the Agenda
7:30 am Check-In & Morning Coffee
8:20 am Chair’s Opening Remarks
Navigating the Evolving TPD Landscape to Understand Future Directions & Drive the Next-Generation of Proximity Therapeutics
8:30 am Panel Discussion: The TPD Investment Landscape: Lessons from Deals in 2025 & Expectations for 2026
9:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing
9:45 am Illuminating New Insights in Targeted Protein Degradation Kinetics, Mechanisms, & Selectivity
10:15 am Expanding Targeted Glue Applications by Recruiting Novel E3 Ligases Across Diverse Targets
10:45 am Morning Break & Networking
Track A: Discovery
Utilizing Novel Discovery Platforms to Find Potent & Selective Molecular Glues to Progress Cures Against Autoimmune & Cancer Indication
11:30 am Orally Bioavailable NRF2 Molecular Glue Degrader Effective in KEAP1-Mutant Cancer
Chief Executive Officer & Co-Founder, Arpeggio Bio
12:00 pm Targeting K-RAS Molecular Glues: Kidnapping a New Ligase to Discover Novel Degraders
Assistant Director, LifeSensors Inc
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development
12:30 pm Lunch Break & Networking
Track A: Discovery
Designing Innovative Activating Molecular Glues Through Structure-Guided Design & AI/ML to Unlock New Therapeutic Opportunities
1:30 pm Structure-Based Development of Non-Degrader Molecular Glues to Selectively Stabilize a Tumor Suppressor Phosphatase Complex
Head of Structural Biology (Rappta Therapeutics); Professor (Case Western Reserve University), Rappta Therapeutics
2:00 pm Panel Discussion: Cracking the Code: Understanding & Measuring Cooperativity in Induced Proximity Modalities
Director - Biophysics, High Throughput Screening & Oncology, Pfizer
Executive Director, Discovery Science, Revolution Medicines
2:30 pm Building A Computational Design Platform For Any Molecular Glue
Chief Executive Officer, Ternary Therapeutics
3:00 pm From Design to Discovery: A Diverse CRBN Molecular Glue Library for HTS Applications
vp, HitChem
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development